Structure Therapeutics (GPCR) Reiterated at Market Outperform by Citizens

September 9, 2026 4:24 AM

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $110.00 price target on Structure Therapeutics (NASDAQ: GPCR).The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found